Candel Therapeutics (CADL) Appoints Maha Radhakrishnan to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- Nasdaq futures slide as AI warnings rattle markets; Nvidia, other chip stocks retreat
- Global AI stocks fall as industry chiefs call for slowing development
- Oil prices continue surge, rising 3% amid Saudi pipeline outage after attack
- BofA sees just 2% upside for the S&P 500 over the next 12 months
- Wall Street's new pair trade: Long software, short chips
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Goldman Sachs tech conference highlights AI spending outlook
- Dell shares surge on record AI server bookings
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- 'No panic anywhere' may be the problem, BofA strategists warn
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
June 6, 2025 8:05 AM EDTAppointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development
NEEDHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Maha Radhakrishnan, M.D., to the Companys Board of Directors (Board) effective June 4, 2025.
We are delighted to welcome Maha as a new member of Candels Board,... More
